A high value choice for both recombination and traditional cloning
|
EZShuttle™ Gateway® PLUS 穿梭克隆带有重组位点和多克隆位点，以实惠的价格满足多种科研需求。 GeneCopeia提供 20,000 种人和15,000小鼠Gateway PLUS穿梭克隆。 EZShuttle™ Gateway PLUS穿梭克隆是EZShuttle™ recombination cloning system的组成部分。EZShuttle™ Gateway PLUS穿梭克隆与Invitrogen公司的Gateway®体系完全兼容，可以简单迅速地将ORF序列转移到任何带有Gateway®的目的表达克隆中。这些克隆可以在大肠杆菌、酵母、杆状病毒、CHO和哺乳动物细胞系、无细胞系统中进行表达和功能分析。
EZShuttle™ Gateway PLUS穿梭克隆的特点
|
|
|
|
|
| 图1。EZShuttle™ Gateway® PLUS ORF/cDNA穿梭克隆可用于重组和传统酶切连接的克隆过程。 |
EZShuttle™ Gateway PLUS提供更多选择
- 带有重组位点 – attL1和attL2位点的存在可以使用Gateway技术方便地将ORF重组到任何目的载体。
- 更高的兼容性 –与其他Gateway克隆相比较，EZShuttle™ Gateway PLUS因为在attL1和起始密码子之间存在多克隆位点，可以完成经典的的酶切-连接克隆。
严格的质量控制体系
人和小鼠的EZShuttle™ Gateway PLUS穿梭克隆源于经过严格筛选的人和小鼠的全长基因。筛选的过程包括多个渠道比对、验证基因序列及注释信息，进行人工纠正，减少冗余、错误的序列。接着，我们将这些经过筛选的ORF 插入到GeneCopoeia高保真克隆技术修饰的Gateway® entry载体。
这些经过严格质量验证OmicsLink™ ORF表达克隆在投递前都经过严格的质量检测。
- 所有的ORF经过全长测序
- PCR扩增验证长度
- 质粒通过了酶切验证
EZShuttle™ Gateway® PLUS穿梭克隆
GeneCopeia提供40,000多种人和小鼠pDONR™载体的预制穿梭克隆。
| 下载 |
| cDNA Clones Manual, Cancellation, QA, License, Warranty |
Note: The purchase of EZShuttle™ Gateway® Shuttle Clones is accompanied by a limited label license under U.S. Patents 5,888,732; 6,143,557; 6,171,861; 6,270,969; 6,277,608 owned by Invitrogen, Corp. only to use the product for the internal research purposes of the purchaser. For information on purchasing a license to use the purchased product for purposes other than the internal research of the purchaser, contact the Director of Licensing at Invitrogen, Corp., 1600 Faraday Avenue, Carlsbad, CA 92008. The trademark Gateway® is owned by Invitrogen Corporation.
- Qu, Y. et al (2013) MiR‐182 and miR‐203 induce mesenchymal to epithelial transition and self‐sufficiency of growth signals via repressing SNAI2 in prostate cells. International Journal of Cancer, DOI: 10.1002/ijc.28056. [Gateway® PLUS Shuttle clone for Human SNAI2; catalog# GC-T1290]
- Anglesio, M. et al (2013) Cancer‐associated somatic DICER1 hotspot mutations cause defective miRNA processing and reverse‐strand expression bias to predominantly mature 3p strands…The Journal of Pathology, Volume 229, Issue 3, pages 400–409, February 2013. [Wild-type DICER1 in a Gateway donor vector].
- O'Donovan, H. et al. (2012) Connective tissue growth factor antagonizes transforming growth factor-beta1/Smadsignalling in renal mesangialcells. Biochem. J. (2012) 441 (499–510) (Printed in Great Britain). [TBRIII ORFEXPRESS™].
- Peschard, P. et al. (2012). Genetic deletion of RALA and RALB small GTPases reveals redundant functions in development and tumorigenesis. Current Biology, Volume 22, Issue 21, 6 November 2012, Pages 2063–2068. [Human RALA (GC-Z1257) and RALB (GC-B0022) cDNAs].
- Schoggins, J.W. et al. (2011) A diverse range of gene products are effectors of the type I interferon antiviral response. Nature 472 (7344): 481-485 [Gateway Plus ORF clones]
- Vitart, V. et al (2008) SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout, Nature Genetics 40, 437 – 442 (2008), [Gateway-compatible entry clones T3097 (SLC2A9_S or GLUT9DN) and T4563 (URAT1 or SLC22A12)].
- Beilina, A. et al (2005) Mutations in PTEN-induced putative kinase 1 associated with recessive parkinsonism have differential effects on protein stability, PNAS April 19, 2005 vol. 102 no. 16 5703-5708, (PINK1 (residues 1-581) in Gateway entry clone).
